ReviewCognitive dysfunction in unipolar depression: Implications for treatment
Introduction
Cognitive symptoms are common among patients with major depressive disorder (MDD) (Fava et al., 2006, Lee et al., 2012, Wagner et al., 2012a, Murrough et al., 2011, Millan et al., 2012), although the true prevalence is not known. We do know cognitive difficulties associated with depression, such as memory impairment, difficulty making decisions, and loss of cognitive flexibility are associated with considerable disability and limited functional recovery (Jaeger et al., 2006, McCall and Dunn, 2003, Naismith et al., 2007). This is particularly troubling because these symptoms frequently persist after remission of a depressive episode (Hasselbalch et al., 2011, Herrera-Guzman et al., 2010, Weiland-Fiedler et al., 2004, Neu et al., 2005, Paelecke-Habermann et al., 2005, Clark et al., 2005, Marcos et al., 1994, Hammar et al., 2010, Airaksinen et al., 2006, Ardal and Hammar, 2011). Nonetheless, there is evidence that cognitive symptoms improve with antidepressant therapy (Wagner et al., 2012a, Herrera-Guzman et al., 2009), and preliminary results show that some classes of antidepressants may be more effective in improving specific cognitive symptoms than others (Herrera-Guzman et al., 2009). These findings suggest that functional outcomes should be monitored during treatment and raise the possibility that interventions which improve cognition may speed functional recovery in patients with MDD (Greer et al., 2010).
Many questions remain regarding the differential expression of cognitive impairment in patients with MDD, such as the timing and duration of their presence, the implications of their presence for long-term outcomes, and the role of treatment to mitigate these symptoms (Wagner et al., 2012a, Millan et al., 2012). This review will focus on: (1) cognitive deficits associated with depression, with an emphasis on those found early in the course of the disease, (2) the neural circuitry associated with cognition and its disruption in depression, (3) the impact of early cognitive dysfunction on recovery, and (4) the impact of antidepressant treatment on cognition. Additionally, the challenges in studying neurocognitive symptoms in patients with MDD will be discussed.
Section snippets
Methods
English language and peer-reviewed publications were obtained by PubMed/Medline (www.pubmed.org) searches. The search terms: major depressive disorder, major depression, and unipolar depression were combined with āfirst episodeā, early, cognition, cognitive, executive function and memory; searches excluded bipolar and psychosis and were limited to papers published in English. A total of 409 records were retrieved and manually screened to eliminate articles primarily discussing stroke,
Conclusions
Despite many challenges in study designs, substantial evidence shows that cognitive symptoms affect a large subset of patients with unipolar depression. Psychomotor speed, executive function and working memory are emerging as the most frequently reported symptoms. Symptoms are present early in the course of the disease and may precede onset of first episode. Nonetheless, antidepressants, particularly those that act at more than one receptor, appear to improve cognition in affected individuals.
Role of funding source
This work has been supported by Takeda Deerfield, IL and H. Lundbeck A/S, Valby DK
Disclaimer statements
Dr. Trivedi has received consulting fees from the following companies: Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., CME Institute of Physicians, Eli Lilly & Company, Evotek, Fabre-Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Neuronetics,
Conflict of interest
No conflict declared.
Acknowledgments
This review was sponsored by the Takeda Pharmaceutical Company, Ltd. and H. Lundbeck A/S. Takeda and Lundbeck suggested the initial concept for the review and approached the lead author based on expertise in the field. Dr. Trivedi and Dr. Greer drafted and reviewed successive versions of the manuscript and had final control over content (neither company reviewed or provided comments on the manuscript content). Medical writing, editorial support, including styling and editing for journal
References (67)
- et al.
Cognitive and social functioning in recovery from depression: results from a population-based three-year follow-up
Journal of Affective Disorders
(2006) - et al.
The role of cognitive impairment in general functioning in major depression
Psychiatry Research
(2010) - et al.
Cognitive functioning in a population-based sample of young adults with a history of non-psychotic unipolar depressive disorders without psychiatric comorbidity
Journal of Affective Disorders
(2008) - et al.
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
Cell
(2003) - et al.
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
Brain Research
(2012) - et al.
Influence of age and executive functioning on verbal memory of inpatients with depression
Journal of Affective Disorders
(2002) - et al.
Enlargement of the amygdala in patients with a first episode of major depression
Biological Psychiatry
(2002) - et al.
Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study
Psychiatry Research
(2012) - et al.
Abnormal neural activities in first-episode, treatment-naive, short-illness-duration, and treatment-response patients with major depressive disorder: a resting-state fMRI study
Journal of Affective Disorders
(2011) - et al.
Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review
Journal of Affective Disorders
(2011)
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder
Psychiatry Research
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder
Journal of Psychiatric Research
Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery
Journal of Affective Disorders
Neurocognitive deficits and disability in major depressive disorder
Psychiatry Research
Attention deficit in depressed suicide attempters
Psychiatry Research
CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine
Journal of Psychiatric Research.
Effects of recurrent major depressive disorder on behavior and cognitive function in female depressed patients
Psychiatry Research
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Journal of Affective Disorders
Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers
Journal of Affective Disorders
A functional magnetic resonance imaging study of verbal working memory in young people at increased familial risk of depression
Biological Psychiatry
Cognitive dysfunctions in recovered melancholic patients
Journal of Affective Disorders
A meta-analysis of depression severity and cognitive function
Journal of Affective Disorders
Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies
Neurobiology of Learning and Memory
Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyperintensities
Journal of Psychiatric Research.
Attention and executive functions in remitted major depression patients
Journal of Affective Disorders
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment
Biological Psychiatry
Evidence for continuing neuropsychological impairments in depression
Journal of Affective Disorders
Altered white matter integrity in first-episode, treatment-naive young adults with major depressive disorder: a tract-based spatial statistics study
Brain Research
Cognitive functions in depressive disorders: evidence from a population-based study
Psychological Medicine Psychological Medicine
Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up
Acta Psychiatrica Scandinavica
Executive dysfunction and long-term outcomes of geriatric depression
Archives of General Psychiatry
Is impairment in cognitive inhibition in the acute phase of major depression irreversible? Results from a 10-year follow-up study
Psychology and Psychotherapy
The MATRICS consensus cognitive battery in patients with bipolar I disorder
Neuropsychopharmacology
Cited by (225)
A systematic review of rehabilitation programs for cognitive impairment related to breast cancer: Different programs at different times?
2024, Annals of Physical and Rehabilitation MedicineCognitive performance in depression in low- and middle-income countries: A systematic review with meta-analytic components
2023, Journal of Affective DisordersThe impact of depressive symptomology, rumination and objective memory performance on subjective cognitive complaints
2023, International Journal of PsychophysiologyClinician perspectives on how digital phenotyping can inform client treatment
2023, Acta PsychologicaāDon't [ruminate], be happyā: A cognitive perspective linking depression and anhedonia
2023, Clinical Psychology ReviewMammillary body and hypothalamic volumes in mood disorders
2023, Journal of Psychiatric ResearchCitation Excerpt :Finally, using high-resolution 7T magnetic resonance imaging (MRI) and image analysis techniques specifically designed for high-precision volumetry of the entire hypothalamus, we were able to observe a left-sided in vivo enlargement in MDD and BD (Schindler et al., 2019). Considering the cognitive deficits in mood disorders (Millan et al., 2012; Trivedi and Greer, 2014) and the limitations of the postmortem approach (Bernstein et al., 2012), we predicted an in vivo volume increase of the MBs in patients compared to controls. : Given the HPA axis dysregulation in stress-related psychiatric disorders (Kendler et al., 1999; Vreeburg et al., 2009; Keller et al., 2017; Mikulska et al., 2021) and the recent neuroimaging finding (Schindler et al., 2019), we also predicted an in vivo enlargement of the hypothalamus without MB (HTh) in patients with mood disorders relative to healthy controls.